DeepQure receives IDE Approval from FDA for its EFS study to treat Resistant Hypertension with its Extravascular Renal Denervation Technology (HyperQureâ„¢)

SEOUL, South Korea, June 10, 2024 /PRNewswire/ — DeepQure, a Seoul based medical device company with a novel, extravascular (laparoscopic approach) solution for renal denervation (RDN), today announced initiation of its Early Feasibility Study (EFS) for the HyperQureâ„¢ system following…